Shares of Intellia Therapeutics jumped 35% overnight as investors anticipate Monday’s Phase 3 results for Lonvo-z, the first in-vivo CRISPR therapy to reach late-stage trials. The treatment aims to ...

We'll know more about the company's medium-term prospects by the end of the year.

There are plenty of reasons, though, to be bullish on the stock, not the least of which is its improved cash position. The ...

Genome‑wide CRISPR screens in primary human T cells reveal human genes that promote or block HIV infection, uncovering potent ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $56.42, moving +1.58% from the previous trading session. The stock exceeded the S&P 500, which registered a gain of 1.05% for the ...

The gene editing treatment targets the relatively common 1717-1G>A splicing mutation, which does not respond to many current CF therapies.

Dr. Swee Lay Thein and Dr. Stuart Orkin won the $3 million Breakthrough Prize in Life Sciences for their work toward a ...

Cancer cells excel at evading detection, but subtle chemical differences set them apart from healthy cells. Now, a team of ...

Researchers announced two major CRISPR breakthroughs: a method to boost production of virus-like particles for gene delivery, and a ThermoCas9 enzyme that can distinguish cancer cells from healthy ...

Researchers have used modified CRISPR to silence the extra chromosome 21 in Down syndrome cells, showing promising ...

View CRISPR Therapeutics AG CRSP stock quote prices, financial information, real-time forecasts, and company news from CNN.

The Pairwise Fulcrum® platform includes proprietary gene editing tools, enzymes, and trait libraries that enable precise genetic changes, unlocking plants’ inherent potential and significantly ...